Anakinra, which targets IL-1-mediated inflammation, is reserved for refractory cases of MIS-C; however, its use in the treatment of MIS-C is not clearly established. The gene discussed is IL1B; the disease is COVID-19–associated multisystem inflammatory syndrome in children.